Dr. Riddhijyoti Talukdar
MBBS, DNB (Radiation Oncology), Fellowship (Neuro-Oncology)
Consultant - Radiation Oncology
Qualification
MBBS, DNB (Radiation Oncology), Fellowship (Neuro-Oncology)
Specialities
Radiation Oncology
Locations
HCG Cancer Centre - Borivali
Experience
8 Years
Introduction
Expertise
Dr. Riddhijyoti Talukdar is a trained radiation oncologist practicing at the HCG Cancer Centre, Borivali.
He is skilled in advanced radiation techniques, namely intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and volumetric-modulated arc therapy (VMAT). He is experienced in both frame-based and frameless stereotactic radiosurgery (SRS), stereotactic radiotherapy (SRT), and stereotactic body radiation therapy (SBRT).
He is specially trained in Neuro-Oncology (the management of brain cancers). His primary interest also lies in managing Head and Neck Cancers, Upper Gastrointestinal Malignancies, Hematolymphoid Malignancies, Breast Cancer, and Gynaecological Malignancies. He is also trained in treating Lower Gastrointestinal, Paediatric, Urological, and other malignancies.
He has a deep understanding of oncology and radiotherapy. He also has excellent communication skills, the utmost passion for medicine, and is extremely compassionate towards his patients. He aims to help each of his patients get the best possible treatment with a personal human touch.
Training and Certifications
Dr. Talukdar has worked as a Senior Research Fellow in Neuro-Oncology department at the Tata Memorial Centre, Mumbai. He has also completed his Senior Residency at a Prestigious Institute.
Recognition
Dr. Talukdar holds a lifetime membership with the Association of Radiation Oncologists of India and the Indian Society of Neuro-Oncology.
He has attended numerous conferences and workshops across India as a faculty member. He has also presented papers at many national and international conferences.
Publications
1. Talukdar, R., Epari, S., Sahay, A., Choudhari, A., Dasgupta, A., Chatterjee, A., Gupta,T., 2021. Endolymphatic sac tumor: single‑institution series of seven cases with an updated review of the literature. European Archives of Oto-Rhino-Laryngology, Published Online 19th August, 2021, DOI: https://doi.org/10.1007/s00405-021-07047-2
2. Tejpal Gupta, Riddhijyoti Talukdar, Sadhana Kannan, Archya Dasgupta, Abhishek Chatterjee, Vijay Patil, Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis, Neuro-Oncology Practice, Volume 9, Issue 5, October 2022, Pages 354–363, https://doi.org/10.1093/nop/npac036
3. R. Talukdar, A. Dasgupta, A. Chatterjee, A. Mishra, O. Roy Chowdhury, K.J. Joshi, A. Sutar, J. Sastri Goda, R.Krishnamurthy, T. Wadasadawala, R. Pathak, P. Maitre, V. Murthy, A. Gupta, P. Mittal, S. Chopra, A. Tibdewal, N.Mummudi, V. Singh, P. Shetty, A. Moiyadi, R. Kinhikar, R. Sarin, J. Agarwal, T. Gupta. (2023). Factors influencing set up margins for image guided frameless stereotactic radiosurgery. Radiotherapy and Oncology, Volume 182 Supplement 1, p.932-933.
4. H. Bhosale, N. Hanumanthappa, S. Basu, P. Chadha, S. Karmakar-Mangaj, A. Srivastava, R. Talukdar, S. Nayak, P. Pawar, A. P.S., J. E.P., S. Pilakkal, K. Bist, M. Nadkarni, B. Ghugare, S. Goyle, I.N. Shaikh, R. Mistry. (2023). Post pandemic ultra-hypofractionated radiation in breast cancer from a tertiary Institution in India. Radiotherapy and Oncology, Volume 182 Supplement 1, p.1042-1043.
5. Talukdar Riddhijyoti, Chatterjee Abhishek, Dasgupta Archya, Kannan Sadhana, Gupta Tejpal. (2022). Efficacy and safety of extended adjuvant temozolomide (>6-cycles) compared to standard 6-cycles of adjuvant temozolomide in newly diagnosed glioblastoma: Systematic review and meta-analysis of randomised controlled trials. Brain Tumour Research and Treatment, Supplement, S165. DOI: 10.14791/btrt.2022.10.F-1256
6. Mukherjee, M., Bhattacharya, J., Shahid, T., Kontham, V., Rajan, R., Talukdar, R. and De, A., 2018. Re-Irradiation in Recurrent Gliomas: Treatment outcome and Prognostic factors. Radiotherapy and Oncology, Volume 133 Supplement 1, p.S675.
7. Mukherjee, M., Shahid, T., Samanta, A., Biswas, L.N., Jawade, A., De, A., Barman, D., Ghosh, T., Sadhukhan, S., Vijayaraghavan, P., Talukdar, R., Saikia, C., Rajan, R., Raj, R., 2019. Comparative study assessing QoL in HNSCC patients treated with Radical Radiation with IMRT vs 3DCRT. Radiotherapy & Oncology, Volume 133 Supplement 1, p.S652.
8. Bhattacharya, J., Jawade, A., Vijayaraghavan, P., Shahid, T., Mukherjee, M., Talukder, R., Samanta, A., Saikia, C., De, A., Barman, D., Ghosh, T. and Sadhukhan, S., 2018. Comparison of patient and physician reported acute toxicities during head and neck cancer radiotherapy. Radiotherapy & Oncology, Volume 133 Supplement 1, p.S651.
9. Shahid, T., Kalyani, N., Modak Das, S., Mukherjee, M., Bhattacharya, J., De, A., Talukdar, R., Samanta, A., Ghosh, T., Barman, D., Sadhukan, S., Vijayaraghavan, P. and Rajan, R., 2019. To compare outcome of Intensive nutritional support with standard practise in head and neck cancer. Radiotherapy & Oncology, Volume 133 Supplement 1, p.S642.
10. Bhattacharya, J., Mukherjee, M., Shahid, T., Rajan, R., Talukdar, R., S, J., Samanta, A. and Vijayaraghavan, P., 2018. Hypofractionated RT in Breast Cancer: Early Experience from a tertiary care centre in India....Read More